Abstract: The present disclosure relates to an inspection system for inspecting objects passing through an inspection area, which inspection area is divided into a plurality of elongated inspection zones having a longitudinal extension, the inspection system comprising: at least one detector and a scanning element adapted for redirecting the detector's field of view to any one of the plurality of elongated inspection zones, wherein the scanning element is adapted to rotate around a first rotational axis and comprises at least two reflective surfaces which redirect the detector's field of view to different inspection zones of the inspection are. A method for inspecting objects passing through an inspection area by an inspection system is also disclosed.

Abstract: A pressure relief valve (PRV) assembly may include PRV stages coupled in end-to-end relation. Each PRV stage may include a PRV body having a cavity therein to receive an adjacent PRV body therein and a fluid passageway fluidly coupled to the cavity. Each PRV stage may also include a PRV valve carried within the cavity and extending within the fluid passageway, and a first biasing member carried within the cavity to bias the PRV valve. Each PRV stage may further include a biasing member stop coupled to the PRV valve within the fluid passageway, and a second biasing member held within the fluid passageway by the biasing member stop and biasing the PRV valve. An end cap may be coupled to a last PRV stage of the PRV stages to hold the first biasing member within the cavity.

Abstract: The present invention relates to a process for producing a sterile liquid pharmaceutical composition suitable for administration by inhalation comprising ensifentrine particles, wherein the process comprises: (a) heating ensifentrine particles at a temperature of from 100° C. to 220° C. to obtain sterile ensifentrine particles; and (b) combining the sterile ensifentrine particles with a sterile liquid vehicle to produce the sterile liquid pharmaceutical composition suitable for administration by inhalation. A process for producing an ampule comprising the sterile liquid pharmaceutical composition is also described.

Abstract: The present invention relates to a process for producing a sterile liquid pharmaceutical composition suitable for administration by inhalation comprising ensifentrine particles, wherein the process comprises: (a) heating ensifentrine particles at a temperature of from 100° C. to 220° C. to obtain sterile ensifentrine particles; and (b) combining the sterile ensifentrine particles with a sterile liquid vehicle to produce the sterile liquid pharmaceutical composition suitable for administration by inhalation. A process for producing an ampule comprising the sterile liquid pharmaceutical composition is also described.

Abstract: A pressure relief valve (PRV) assembly may include a housing having an opening therein, an interior cavity, a passageway extending between the opening and the interior cavity, and a flange extending within the passageway adjacent the opening. The PRV assembly may also include a first stage valve carried within the interior cavity, and a second stage valve fluidly coupled in series with the first stage valve. The second stage valve may include an enlarged head carried within the opening and a shaft extending from the enlarged head through the passageway to the interior cavity. The shaft may have a proximal end coupled to the enlarged head and an opposing enlarged distal end adjacent the interior cavity. A biasing member may be between the enlarged distal end and the flange. The biasing member may be configured to bias the first and second stage valves to a closed position.

Abstract: Systems and methods for desalinating a liquid are provided. A desalination system may include a main container and may be configured to provide at least one of an electric field or a magnetic field through the main container to control a distribution of ions in a liquid in the main container.

Abstract: The present invention relates to a process for producing a sterile liquid pharmaceutical composition suitable for administration by inhalation comprising ensifentrine particles, wherein the process comprises: (a) heating ensifentrine particles at a temperature of from 100° C. to 220° C. to obtain sterile ensifentrine particles; and (b) combining the sterile ensifentrine particles with a sterile liquid vehicle to produce the sterile liquid pharmaceutical composition suitable for administration by inhalation. A process for producing an ampule comprising the sterile liquid pharmaceutical composition is also described.

Abstract: The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation comprising: (i) ensifentrine particles; (ii) glycopyrrolate; and (iii) a diluent, which diluent comprises water, wherein: the glycopyrrolate is dissolved in the diluent; the concentration of glycopyrrolate is less than or equal to 5.0 mg/mL; and the pH of the liquid pharmaceutical composition is from 3.0 to 6.0. The invention also relates to a nebuliser comprising the liquid pharmaceutical composition.

Abstract: Systems and methods for desalinating a liquid are provided. A desalination system may include a main container and may be configured to provide at least one of an electric field or a magnetic field through the main container to control a distribution of ions in a liquid in the main container.

Abstract: Embodiments of a power provision system of the present invention generally include a transformer, a drive assembly, a motor control center, rectifiers, circuit breakers, and a cooling system, all of which are enclosed in a cabinet that is divided into a plurality of compartments that house various components and that is adapted and configured to be skid mounted on a trailer. In one embodiment, high voltage power is supplied to the power provision system, wherein it is stepped down to lower voltages by the transformer and the lower voltage power is utilized to drive a fracking pump motor via the drive assembly, as well as auxiliary equipment, such as the cooling system, via the motor control center. Embodiments of a method of using the power provision system are also provided.

Abstract: The present invention relates to a pharmaceutically acceptable acid addition salt of: (i) 9,10-dimethoxy-2-(2,4,6-tri-methylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554); and (ii) ethane-1,2-disulfonic acid, ethanesulfonic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid.

Abstract: The present invention relates to a dry powder pharmaceutical composition suitable for administration by inhalation comprising: (i) ensifentrine particles; (ii) coarse lactose particles having a Dv50 of from 40 ?m to 80 ?m; and (iii) fine lactose particles having a Dv50 of from 5 ?m to 10 ?m, wherein: the fine lactose particles are present in an amount of from 0.1 wt % to 6.0 wt % relative to the total weight to the dry powder pharmaceutical composition. Also provided is a dry powder inhaler comprising the dry powder pharmaceutical composition and medical use of the dry powder pharmaceutical composition.

Abstract: The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation which comprises a diluent and a suspension of particles of 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554) or a pharmaceutically acceptable salt thereof. Also described is a liquid pharmaceutical composition according to the invention for use in the treatment of the human or animal body.

Abstract: Embodiments of a power provision system of the present invention generally include a transformer, a drive assembly, a motor control center, rectifiers, circuit breakers, and a cooling system, all of which are enclosed in a cabinet that is divided into a plurality of compartments that house various components and that is adapted and configured to be skid mounted on a trailer. In one embodiment, high voltage power is supplied to the power provision system, wherein it is stepped down to lower voltages by the transformer and the lower voltage power is utilized to drive a fracking pump motor via the drive assembly, as well as auxiliary equipment, such as the cooling system, via the motor control center. Embodiments of a method of using the power provision system are also provided.

Abstract: The present invention relates to a pharmaceutically acceptable acid addition salt of: (i) 9,10-dimethoxy-2-(2,4,6-tri-methylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554); and (ii) ethane-1,2-disulfonic acid, ethanesulfonic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid.

Abstract: The present invention relates to a pharmaceutically acceptable acid addition salt of: (i) 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554); and (ii) ethane-1,2-disulfonic acid, ethanesulfonic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid.

Abstract: An improved mist generating apparatus is provided, the apparatus having a longitudinal axis (L), and first and second opposing nozzle surfaces (100,102) which define a nozzle between them. A first process fluid passage (28) has an inlet connectable to a supply of process fluid, and a process fluid outlet (110) on one or the first and second nozzle surfaces (100,102) such that the process fluid outlet (110) opens into the nozzle. The nozzle has a nozzle inlet (104) connectable to a supply of driving fluid, a nozzle outlet (108), and a throat portion (106) intermediate the nozzle inlet (104) and nozzle outlet (108). The nozzle throat (106) has a cross sectional area which is less than that of both the nozzle inlet (104) and the nozzle outlet (108). The nozzle extends radially away from the longitudinal axis (L) such that the nozzle defines a rotational angle about the longitudinal axis (L).

Abstract: A printing method includes programming a 3D printer to print a three-dimensional product, the three-dimensional product being one of a coin, a round, or a bar; selecting a precious metal from one of gold, silver, and copper; providing the 3D printer with the precious metal; directing the 3D printer to create the three-dimensional product with the precious metal; and applying a layer of graphene to a surface of the three-dimensional product; the layer of graphene provides protection to the three-dimensional product.

Abstract: Interactive system provides training and assessments relating to joint stabilization capabilities and reaction-based performance for diverse populations. This system may enhance the subject's ability to generate and deliver power as a direct byproduct of properly timed decelerations originating with the effectors and supported by the verticality of the spine. Said decelerations also provide functional means for improving joint stabilization capabilities via improved co-contraction of the shoulder(s) joints and other anatomical locations on the subject. The resulting data may serve as the basis for predictive analytics relating to joint stabilization and the associated risk of orthopedic injuries. This system may also train/improve the dampening of internal forces resulting from aggressive weight bearing movements, and more effectively dissipate the force of received physical impacts.

Abstract: The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation which comprises a diluent and a suspension of particles of 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554) or a pharmaceutically acceptable salt thereof. Also described is a liquid pharmaceutical composition according to the invention for use in the treatment of the human or animal body.